| Phase 3 |
| NCT06281964 |
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring… |
Non-Small-Cell Lung Cancer |
Enrolling by Invitation |
2026-04-23 |
| NCT06970782 |
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With… |
Non-Small-Cell Lung Cancer |
Not Yet Recruiting |
2025-05-21 |
| Phase 2 |
| NCT07336732 |
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet… |
Non-Small-Cell Lung Cancer |
Recruiting |
2026-03-20 |
| NCT06574347 |
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally… |
Non-Small-Cell Lung Cancer |
Recruiting |
2025-05-21 |
| NCT06015503 |
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation… |
NSCLC (Non-small Cell Lung Cancer) |
Active, Not Recruiting |
2026-05-22 |
| Phase 1/2 |
| NCT07538804 |
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell… |
Non-Small Cell Lung Cancer |
Recruiting |
2026-07-06 |
| NCT06343064 |
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET… |
Non-Small-Cell Lung Cancer |
Recruiting |
2025-05-21 |
| Phase 1 |
| NCT06307795 |
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic… |
Locally Advanced or Metastatic Solid Tumors |
Recruiting |
2026-04-17 |
| NCT06716138 |
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid… |
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration |
Recruiting |
2026-03-13 |
| NCT06046495 |
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer |
Non-Small Cell Lung Cancer |
Recruiting |
2025-04-23 |
| NCT06328439 |
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors |
Locally Advanced or Metastatic Solid Tumors |
Active, Not Recruiting |
2026-03-25 |